Stockreport

Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis [Yahoo! Finance]

Arcutis Biotherapeutics, Inc. - Common stock  (ARQT) 
PDF Arcutis Biotherapeutics, Inc. Phase 1a/1b, first-in-human study to evaluate safety and tolerability for investigational ARQ-234 in healthy volunteers and adults with [Read more]